What is the protocol for initiating unfractionated heparin in a patient receiving warfarin who has developed a new ischemic limb?

Immediate Heparin Initiation for Acute Limb Ischemia in Warfarin Patients

In a patient on warfarin who develops acute limb ischemia, immediately start therapeutic unfractionated heparin (UFH) regardless of the current INR, using a weight-based bolus of 80 U/kg followed by 18 U/kg/hour infusion, unless active bleeding or other absolute contraindications exist 1, 2.

Immediate Actions

1. Start Heparin Without Delay

• Do not wait for INR results or warfarin reversal
• Acute limb ischemia is a vascular emergency where immediate anticoagulation prevents clot propagation and distal embolization 1, 3
• The goal is to limit ischemic injury while revascularization plans are determined

2. Standard UFH Dosing Protocol

Initial bolus: 80 U/kg IV push 4, 2

Continuous infusion: 18 U/kg/hour 4, 2

Monitoring target: aPTT ratio of 1.5-2.5 times control (approximately 50-70 seconds), corresponding to anti-factor Xa levels of 0.3-0.7 IU/mL 4, 5

3. Monitoring Schedule

• Check aPTT 6 hours after starting infusion 5
• Adjust using a weight-based nomogram validated at your institution 4
• Recheck aPTT 6 hours after each dose adjustment until therapeutic
• Once stable, monitor aPTT every 24 hours

Critical Considerations for Warfarin Overlap

The Warfarin Effect on aPTT

Important caveat: Warfarin therapy substantially increases aPTT independent of heparin effect—approximately 20 seconds for each 1.0 increase in INR 6. This means:

• Your aPTT may appear falsely elevated if the patient has a therapeutic or supratherapeutic INR
• Consider checking anti-factor Xa levels (target 0.3-0.7 IU/mL) for more accurate heparin monitoring in patients with elevated INR 4, 7
• Do not reduce heparin doses prematurely based solely on elevated aPTT if INR is elevated

Timing of aPTT Measurement

If the patient received recent heparin exposure before your evaluation, draw aPTT at least:

• 5 hours after last IV heparin bolus
• 4 hours after stopping continuous IV infusion
• 24 hours after subcutaneous heparin 8

Why UFH Over LMWH in This Setting

While LMWH is generally preferred for VTE treatment 4, UFH is specifically recommended for acute limb ischemia because:

1. Short half-life allows rapid titration as revascularization plans evolve 1
2. Immediate reversibility with protamine if urgent surgery is needed
3. Established practice in acute arterial thrombosis 1, 3
4. Better monitoring in unstable patients who may need procedures

Absolute Contraindications to Heparin

Do not start heparin if:

• Active major bleeding (>2 units transfused in 24 hours) 9
• Recent CNS bleed or high-risk intracranial lesion 9
• History of heparin-induced thrombocytopenia (HIT) 2
• Known severe hypersensitivity to heparin or pork products 2

If HIT history exists: Use a direct thrombin inhibitor (argatroban or bivalirudin) instead 1

Monitoring for Complications

Heparin-Induced Thrombocytopenia (HIT)

• Check baseline platelet count before starting heparin 4
• Monitor platelets every 2-3 days from day 4 to day 14 4
• HIT risk with UFH can be as high as 5% 4
• Suspect HIT if platelet count drops ≥50% from baseline, typically 5-10 days after starting heparin 4

Bleeding Risk

• Higher risk in patients >60 years old, particularly women 2
• Monitor for unexplained drop in hematocrit or blood pressure 2
• Check hemoglobin/hematocrit every 2-3 days 9

Duration and Transition

• Continue UFH until definitive revascularization is performed 1
• If transitioning back to warfarin after revascularization, overlap UFH with warfarin for at least 5 days and until INR ≥2.0 for 24 hours 10, 4, 2
• Do not discontinue heparin until INR is therapeutic for 2 consecutive days 10

Common Pitfalls to Avoid

1. Delaying heparin while waiting for diagnostic imaging or INR results—start immediately on clinical diagnosis
2. Under-dosing due to fear of bleeding in a patient already on warfarin—use full weight-based dosing
3. Over-relying on aPTT in patients with elevated INR—consider anti-Xa levels
4. Stopping heparin too early when transitioning to warfarin—maintain overlap until INR therapeutic ≥24 hours
5. Forgetting HIT monitoring—check platelets regularly, especially days 4-14